EGF treated A-431 cells were processed by using the PhosphoCruz™ Protein Purification System sc-24964. Fig. 1: Blots were probed with phosphotyrosine antibody, sc-508, detecting tyrosine phosphorylated EGFR. Lanes A/B: unbound column fractions. Lanes C/D: bound column (phosphoprotein enriched) fractions. Lanes E/F: whole cell lysates prepared from untreated and EGF-treated cultures, respectively. Fig. 2: The same samples shown in Fig. 1 were analyzed with antibody to HSP 60, sc-13115.
EGF treated A-431 cells were processed by using the PhosphoCruz™ Protein Purification System sc-24964. Fig. 1: Blots were probed with phosphotyrosine antibody, sc-508, detecting tyrosine phosphorylated EGFR. Lanes A/B: unbound column fractions. Lanes C/D: bound column (phosphoprotein enriched) fractions. Lanes E/F: whole cell lysates prepared from untreated and EGF-treated cultures, respectively. Fig. 2: The same samples shown in Fig. 1 were analyzed with antibody to HSP 60, sc-13115.
PhosphoCruzTM Protein Purification System: sc-24964
EGF treated A-431 cells were processed by using the PhosphoCruz™ Protein Purification System sc-24964. Fig. 1: Blots were probed with phosphotyrosine antibody, sc-508, detecting tyrosine phosphorylated EGFR. Lanes A/B: unbound column fractions. Lanes C/D: bound column (phosphoprotein enriched) fractions. Lanes E/F: whole cell lysates prepared from untreated and EGF-treated cultures, respectively. Fig. 2: The same samples shown in Fig. 1 were analyzed with antibody to HSP 60, sc-13115.
PhosphoCruz™ Protein Purification System: sc-24964
affinity purification system devised to enrich/isolate phosphoproteins from cell lysates and tissue extracts for phosphorylation studies; proteins that carry a phosphate group are retained on the column while non-phosphorylated and undesired contaminants pass through
typical phosphoenriched protein yield is 5-10% of total protein
contains materials required for six individual phosphoprotein enrichment procedures including six single-use columns, 100 ml 2X Binding/Wash Buffer, 30 ml Eluting Buffer, 150 µl each Phosphatase Inhibitor Cocktails 1 and 2, and six ultrafiltration concentrators for concentrating phosphoenriched protein post-purification